Opens in a new tab

Dr. Li Guoxin

Chinese name: 李国新
Professor, Chief Physician, Doctoral Supervisor, Vice President . Gastrointestinal Surgery (General Surgery)
Professor Li Guoxin is Vice President of Nanfang Hospital of Southern Medical University and academic leader of gastrointestinal surgery. A leading figure in laparoscopic gastrointestinal surgery in China, he founded the Chinese Laparoscopic Gastrointestinal Surgery Study Group and led the CLASS-01 trial that changed international guidelines for locally advanced gastric cancer.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

5000+
Laparoscopic gastrointestinal surgeries performed
31
Authorized patents (invention and utility model)
11
Software copyrights

  • The Physician

About Dr. Li Guoxin

Professor Li Guoxin is Vice President of Nanfang Hospital of Southern Medical University and academic leader of gastrointestinal surgery, and a Fellow of the Royal College of Surgeons of England. He has devoted thirty-five years to gastrointestinal tumour surgery, performing more than ten thousand major operations, and created a precise minimally invasive surgical system for gastric cancer. He proposed a new anatomy for minimally invasive gastric surgery, founded the Chinese Laparoscopic Gastrointestinal Surgery Study Group and led the CLASS-01 trial, which provided the first level-one evidence that laparoscopic surgery is safe and effective for locally advanced gastric cancer. He is a chief scientist of a National Key R&D Programme project.
1、Vice President of Nanfang Hospital of Southern Medical University
2、Academic leader and former Director of General Surgery at Nanfang Hospital
3、Founder of the Chinese Laparoscopic Gastrointestinal Surgery Study Group (CLASS)
4、Fellow of the Royal College of Surgeons of England (FRCS)
5、Chief scientist of a National Key R&D Programme project
6、Recipient of a National Health Contribution Outstanding Young and Middle-aged Expert award and the Guangdong Ding Ying Science and Technology Award

Dr. Li Guoxin ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Gastric cancer

He performs laparoscopic and robotic radical gastrectomy with D2 lymphadenectomy for gastric cancer, using a precise minimally invasive technique to remove the tumour and lymph nodes completely, reduce surgical trauma and speed recovery for patients with early and locally advanced gastric cancer.

Colorectal cancer

He treats colon and rectal cancer with laparoscopic and minimally invasive surgery, combining complete mesocolic and total mesorectal excision with individualised treatment planning to achieve radical resection, preserve function and improve long-term survival for patients with these common gastrointestinal tumours.

Gastrointestinal stromal tumour and benign disease

He removes gastrointestinal stromal tumours and manages benign stomach and bowel diseases such as hernia, using minimally invasive techniques to achieve complete resection, repair defects and reduce postoperative pain and hospital stay for patients with these common surgical conditions in routine clinical practice.

More：early gastric cancer——laparoscopic resection; gastric lymph node metastasis——precision prediction; peritoneal metastasis——conversion therapy; hernia——repair; colorectal cancer——minimally invasive surgery

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. CLASS-01 Trial: Laparoscopic versus Open Distal Gastrectomy for Advanced Gastric Cancer
This multicenter randomized trial led by Li Guoxin assigned one thousand fifty six patients with locally advanced gastric cancer to laparoscopic or open distal gastrectomy with D2 lymphadenectomy. The five-year overall survival rates were seventy two point six and seventy six point three percent, showing laparoscopic surgery is not inferior when performed by experienced surgeons at high-volume centres.
2. Pooled Analysis of KLASS-02 and CLASS-01: Long-Term Outcomes of Laparoscopic Gastrectomy
This individual patient data meta-analysis pooled the Korean KLASS-02 and Chinese CLASS-01 trials to compare laparoscopic with open distal gastrectomy in around one thousand eight hundred patients with locally advanced gastric cancer. Five-year overall survival was about eighty three percent in both groups, confirming the oncological safety of minimally invasive gastrectomy.
3. Laparoscopic Endoscopic Cooperative Surgery versus Endoscopic Submucosal Dissection for Gastric GIST
This propensity-score matched study from Li Guoxin’s team compared laparoscopic and endoscopic cooperative surgery with endoscopic submucosal dissection for small gastric gastrointestinal stromal tumours. Cooperative surgery produced fewer intraoperative complications and less bleeding, with equal postoperative courses and no significant difference in recurrence, supporting it as a safe minimally invasive option for selected gastric GIST patients.
4. Surgical Innovations to Target Gastric and Liver Cancers
A Nature spotlight feature describes how Li Guoxin, director of general surgery at Nanfang Hospital, introduced new standards for minimally invasive gastric cancer surgery, from lymph node dissection to digestive tract reconstruction. Building on laparoscopy, the work reduces surgical bleeding and pain, improves wound appearance and speeds postoperative recovery for patients with gastric cancer.
5. Clinical Trials on Gastric Cancer Surgery in China
This review summarises gastric cancer surgery trials conducted in mainland China, including the CLASS series led by Li Guoxin that examined laparoscopic distal gastrectomy, spleen-preserving lymph node dissection, digestive reconstruction and image-guided minimally invasive treatment. It documents how the CLASS group advanced evidence for minimally invasive gastric cancer surgery and improved patient quality of life.
6. CLASS-01 Trial Summary: Safety of Laparoscopic Gastrectomy for Advanced Gastric Cancer
The CLASS-01 randomized controlled trial directed by Li Guoxin was the first completed multicenter study comparing long-term outcomes of laparoscopic and open distal gastrectomy for locally advanced gastric cancer in China. Its three-year and five-year results showed comparable disease-free and overall survival, providing high-level evidence that supports laparoscopic gastrectomy as a standard treatment.
  • Affiliated Hospital

Where Dr. Li Guoxin practices

Guangzhou

Nanfang Hospital, Southern Medical University

Chinese name: 南方医科大学南方医院
Nanfang Hospital, founded in 1941 as a wartime rear hospital and now a national regional medical center of Southern Medical University, is a Grade-A tertiary hospital holding 5 national key disciplines, 17 national key specialties and a nationally leading nephrology program.
Since 1941
85 years of care
2,225
Licensed beds
17
National key specialties
3.32 million (2021)
Licensed beds
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Li Guoxin?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Li Guoxin.